Double blind, placebo controlled randomised trial assessing the efficacy of endothelin-1 receptor antagonism against placebo in the prevention of microvascular injury in patients with non-ST elevation acute coronary syndrome (NSTEACS) undergoing percutaneous coronary intervention: the ENDORA-PCI trial

Trial Profile

Double blind, placebo controlled randomised trial assessing the efficacy of endothelin-1 receptor antagonism against placebo in the prevention of microvascular injury in patients with non-ST elevation acute coronary syndrome (NSTEACS) undergoing percutaneous coronary intervention: the ENDORA-PCI trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Acute coronary syndromes
  • Focus Pharmacodynamics
  • Acronyms ENDORA-PCI
  • Most Recent Events

    • 14 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top